Pfizer has sold a significant portion of its stake in German drugmaker BioNTech SE, a more than five years after the two ...

The financial markets responded immediately, with BioNTech shares declining as much as 5% in pre-market trading. This partnership has historically formed the cornerstone of BioNTech's commercial ...

Five years after their celebrated collaboration on a COVID-19 vaccine, Pfizer has initiated a significant divestment, selling ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

The strategic partnership that yielded one of history's most successful vaccines reached a turning point this week. Pfizer ...

BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.

CereCura was co-founded by renowned scientist and UBC professor Pieter Cullis, who developed LNPs, the drug delivery system ...

Solorz, the media and telecoms baron behind Poland’s Polsat TV channel, asked a US Federal Court late last month to compel daughter Aleksandra Żak to hand over documents related to the battle.

The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 ...